

OncoTherapy Science, Inc.

May 12, 2020

Announcement of an additional investigational site opening for the Phase I clinical study of combination of OTSGC-A24 and Immune Checkpoint Inhibitor in Patients with Gastric Cancer

OncoTherapy Science, Inc. (President & CEO: Jae-Hyun Park; hereinafter “OncoTherapy”) today announces that the patient recruitment for Phase I clinical study of a Combination of OTSGC-A24 and Immune Checkpoint Inhibitor for Gastric Cancer will be initiated in Severance Hospital, Yonsei University Health System, Korea.

This investigator-initiated study has been started in NUH, Singapore in 2019, and OncoTherapy provides the study drug OTSGC-A24 as a collaborator. The study protocol is approved by Ministry of Food and Drug Safety, Korea and Severance Hospital will initiate the patient recruitment as an additional clinical investigation site for this study.

This study is designed to evaluate safety, objective response as well as to evaluate an induction of peptide-specific CTL response after administration of OTSGC-A24, Nivolumab and Ipilimumab as a combination in patients with inoperable or metastatic gastric cancer.

OTSGC-A24 is the cocktail peptide vaccine product which contains multiple peptides targeting the tumor-specific antigens, highly expressed in gastric cancer cells. Each peptide contained in this cocktail is expected to induce cytotoxic T lymphocyte. Phase I clinical study of OTSGC-A24 as a single agent for refractory gastric cancer was conducted in Singapore, Korea and Japan and had been completed with favorable results on safety and immune reactivity.